<DOC>
	<DOCNO>NCT00264043</DOCNO>
	<brief_summary>The primary objective evaluate use AngioGuard™ device combine Bx Velocity™ patient outcome one month .</brief_summary>
	<brief_title>The Study Evaluate Patient Outcome Using Distal Protection Combined With BX Velocity .</brief_title>
	<detailed_description>This prospective , non-randomized , multi-center trial . Patients treat AngioGuard™ device Bx Velocity™ stent follow six-months post-procedure .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Unstable angina pectoris ( Braunwald classification B &amp; C , IIIIII , native vessel ) lesion locate SVG ; Single de novo restenotic lesion require treatment major native coronary artery saphenous vein graft ; The vessel diameter place AngioGuard™ device must &gt; 3 &lt; 5.5 mm ( 6.5 7mm AngioGuard™ available ) ; Target lesion stenosis &gt; 50 % &lt; 100 % ( TIMI 1 ) . A Qwave nonQwave myocardial infarction within precede 72 hour unless CK CKMB enzymes back normal ; More one coronary artery 100 % occlude ; Patient unprotected leave main coronary disease &gt; 50 % stenosis ; Patient ostial target lesion ; Significant ( &gt; 50 % ) untreated stenosis proximal distal target lesion treat procedure , since may require revascularization impede runoff ; Ejection fraction &lt; 30 % ; Totally occlude vessel ( TIMI 0 Level ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
</DOC>